United Therapeutics Corporation

United Technology Corporation

Robert Roscigno

Thomas Schmehl

Werner Seeger

Lewis J Rubin

Robert Voswinckel

Horst Olschewski

Carl Sterritt

Michael Wade

Roger Jeffs

Martine A Rothblatt

Deborah Strootman

Gilles Cloutier

Kathryn Bronstein

James W Crow

Shelmer D Blackburn, Jr

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Treprostinil administration by inhalation

The present disclosure relates to novel methods for using treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The disclosure also relates to kits for treatment and/or prevention of ischemic lesions, which include an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Use of treprostinil to treat and prevent ischemic lesions

An improved treatment for peripheral vascular disease is described using 9-deoxy-2',9-.alpha.-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene) -13,14-dihydro-prostaglandin F.sub.1.

Use of

Growing community of inventors

Chapel Hill, NC, United States of America

Robert Roscigno